Potency evaluation of tissue engineered and regenerative medicine products

Trends in Biotechnology

Volumn 31, Issue 9, 2013, Pages 505-514

  Guthrie, Kelly ^a   Bruce, Andrew ^a   Sangha, Namrata ^a   Rivera, Elias ^a   Basu, Joydeep ^a  

^a Tengion Inc   (United States)

Author keywords

Cell therapy; Potency; Regenerative medicine; Tissue engineering

Indexed keywords

CELL BASED THERAPIES; CELL THERAPY; MECHANISTIC PATHWAYS; POTENCY; POTENTIAL MECHANISM; QUANTITATIVE EVALUATION; REGENERATIVE MEDICINE; THERAPEUTIC OUTCOMES;

BIOACTIVITY; TISSUE ENGINEERING;

TISSUE;

BIOMATERIAL;

BIOLOGICAL ACTIVITY; CELL COUNT; CELL VIABILITY; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; TISSUE ENGINEERING; TREATMENT OUTCOME;

HARNESS;

EID: 84882660585     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2013.05.007     Document Type: Review

References (41)

1. Basu J., Ludlow J.W. Developmental engineering the kidney: leveraging principles of morphogenesis for renal regeneration. Birth Defects Res. C: Embryo Today 2012, 96:30-38.
2. Andree B., et al. Small intestinal sub-mucosa segments as matrix for tissue engineering: review. Tissue Eng. Part B: Rev. 2013, 19:279-291.
3. Carmen J., et al. Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development. Regen. Med. 2012, 7:85-100.
4. Rayment E.A., Williams D.J. Mind the gap: challenges in characterizing and quantifying cell and tissue based therapies for clinical translation. Stem Cells 2010, 28:996-1004.
5. Basu J., Ludlow J.W. Platform technologies for tubular organ regeneration. Trends Biotechnol. 2010, 28:526-533.
6. Basu J., Ludlow J.W. Tissue engineering of tubular and solid organs: an industry perspective. Advances in Regenerative Medicine 2011, 235-260. Intech Open. S. Wislet-Gendebien (Ed.).
7. Bravery C.A., et al. Potency assay development for cellular therapy products: an ISCT review of the requirements and experiences in the industry. Cytotherapy 2013, 15:9-19.
8. Center for Biologics Evaluation and Research Guidance for Industry: Potency Tests For Cellular And Gene Therapy Products 2011, US Food and Drug Administration.
9. Kretlow J.D., et al. Donor age and cell passage affects differentiation potential of murine bone-marrow derived stem cells. BMC Cell Biol. 2008, 9:60.
10. Prockop D. Repair of tissues by adult stem/progenitor cells (MSCs): controversies, myths and changing paradigms. Mol. Ther. 2009, 17:939-946.
11. Caplan A.I., Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011, 9:11-15.
12. Jiao J., et al. A mesenchymal stem cell potency assay. Methods Mol. Biol. 2011, 677:221-231.
13. Bai L., et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat. Neurosci. 2012, 15:862-870.
14. Basu J., et al. Functional evaluation of primary renal cell/biomaterial neo-kidney augment prototypes for renal tissue engineering. Cell Transplant. 2011, 20:1771-1790.
15. Xu Q., et al. Constitutive release of cytokines by human oral keratinocytes in an organotypic culture. J. Oral Maxillofac. Surg. 2009, 67:1256-1264.
16. Camussi G., et al. Role of stem cell derived micro-vesicles in the paracrine action of stem cells. Biochem. Soc. Trans. 2013, 41:283-287.
17. Lehman N., et al. Development of a surrogate angiogenic potency assay for clinical grade stem cell production. Cytotherapy 2012, 14:994-1004.
18. Medicetty S., et al. Percutaneous adventitial delivery of allogeneic bone marrow-derived stem cells via infarct-related artery improves long-term ventricular function in acute myocardial infarction. Cell Transplant. 2012, 21:1109-1120.
19. Mansbridge J. Commercial considerations in tissue engineering. J. Anat. 2006, 209:527-532.
20. Basu J., et al. Expansion of the human adipose derived stromal vascular cell fraction yields a population of smooth muscle-like cells with markedly distinct phenotypic and functional properties relative to mesenchymal stem cells. Tissue Eng. Part C: Methods 2011, 17:843-860.
21. Basu J., Ludlow J.W. Developments in Tissue Engineered and Regenerative Medicine Products: A Practical Approach 2012, Woodhead Publishing.
22. Jayo M.J., et al. Early cellular and stromal responses in the regeneration of a functional mammalian bladder. J. Urol. 2008, 180:392-397.
23. Basu J., et al. Regeneration of native-like neo-urinary tissue from non-bladder cell sources. Tissue Eng. Part A 2012, 18:1025-1034.
24. Shah S., et al. Cellular basis of tissue regeneration by omentum. PLoS ONE 2012, 7:e38368.
25. Guthrie K., et al. Migration assay to evaluate cellular interactions with biomaterials for tissue engineering/regenerative medicine applications. Methods Mol. Biol. 2013, 1001:189-196.
26. Basu J., et al. Extension of bladder-based organ regeneration platform for tissue engineering of esophagus. Med. Hypotheses 2012, 78:231-234.
27. Basu J., et al. Regeneration of rodent small intestine tissue following implantation of scaffolds seeded with a novel source of smooth muscle cells. Regen. Med. 2011, 6:721-731.
28. Soncin S., et al. A practical approach for the validation of sterility, endotoxin and potency testing of bone marrow mononucleated cells used in cardiac regeneration in compliance with good manufacturing practice. J. Transl. Med. 2009, 7:78.
29. Dahl S., et al. Readily available tissue engineered vascular grafts. Sci. Transl. Med. 2011, 3:68ra9.
30. Kelley R., et al. A population of selected renal cells augments renal function and extends survival in the ZSF1 model of progressive diabetic nephropathy. Cell Transplant. 2013, 22:1023-1039.
31. Guimaraes-Souza N.K., et al. In vitro reconstitution of human kidney structures for renal cell therapy. Nephrol. Dial. Transplant. 2012, 27:3082-3090.
32. Noiman T., et al. A rapid in vivo assay system for analyzing the organogenetic capacity of human kidney cells. Organogenesis 2011, 7:140-144.
33. Genheimer C., et al. Molecular characterization of the regenerative response induced by intra-renal transplantation of selected renal cells in a rodent model of chronic kidney disease. Cells Tissues Organs 2012, 196:374-384.
34. Zeisberg M., et al. Extra-cellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am. J. Pathol. 2002, 160:2001-2008.
35. Kelley R., et al. A tubular cell-enriched subpopulation of primary renal cells improves survival and augments kidney function in a rodent model of chronic kidney disease. Am. J. Physiol. Renal Physiol. 2010, 299:F1026-F1039.
36. Dudas P.L., et al. BMP7 fails to attenuate TGFβ1 induced epithelial-mesenchymal transition in human proximal tubule epithelial cells. Nephrol. Dial. Transplant. 2009, 24:1406-1416.
37. Hall H., et al. Hematopoietic stem cell potency for cellular therapeutic transplantation. Advances in Hematopoietic Stem Cell Research 2012, Intech Open.
38. Roh J.D., et al. Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation mediated process of vascular remodeling. PNAS 2010, 107:4669-4674.
39. Ratliff B.B., et al. Mesenchymal stem cells, used as bait, disclose tissue binding sites: a tool in the search for the niche?. Am. J. Pathol. 2010, 177:873-883.
40. Higano C.S., et al. Sipulecel-T. Nat. Rev. Drug Discov. 2010, 9:513-514.
41. Schwartz S.D., et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012, 379:713-720.